US7560446B2 - Use of angiotensin II receptor antagonists for treating acute myocardial infarction - Google Patents

Use of angiotensin II receptor antagonists for treating acute myocardial infarction Download PDF

Info

Publication number
US7560446B2
US7560446B2 US10/859,776 US85977604A US7560446B2 US 7560446 B2 US7560446 B2 US 7560446B2 US 85977604 A US85977604 A US 85977604A US 7560446 B2 US7560446 B2 US 7560446B2
Authority
US
United States
Prior art keywords
angiotensin
acute
pharmaceutically acceptable
active ingredient
acceptable salt
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Fee Related, expires
Application number
US10/859,776
Other versions
US20040224999A1 (en
Inventor
Jessica M Mann
Pascale Oddou
Eric M Neuhart
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novartis AG
Original Assignee
Novartis AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8242650&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=US7560446(B2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from PCT/EP2000/000525 external-priority patent/WO2000044378A1/en
Application filed by Novartis AG filed Critical Novartis AG
Priority to US10/859,776 priority Critical patent/US7560446B2/en
Publication of US20040224999A1 publication Critical patent/US20040224999A1/en
Application granted granted Critical
Publication of US7560446B2 publication Critical patent/US7560446B2/en
Adjusted expiration legal-status Critical
Expired - Fee Related legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4174—Arylalkylimidazoles, e.g. oxymetazolin, naphazoline, miconazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Definitions

  • the enzyme cascade of the renin-angiotensin system comprises a series of biochemical events and, as is well known, there are a variety of approaches for using regulatory intervention to open up treatment possibilities, for example treatment of hypertension.
  • Angiotensinogen an ⁇ 2-macroglycoprotein
  • renin an ⁇ 2-macroglycoprotein
  • angiotensin I an ⁇ 2-macroglycoprotein
  • ACE angiotensin converting enzyme
  • angiotensin II The vasoconstrictive effects of angiotensin II are brought about by its action on the smooth muscle cells, and by stimulating formation of the adrenergic hormones adrenaline and noradrenaline and by increasing the activity of the sympathetic nervous system due to the formation of noradrenaline.
  • angiotensin II affects the electrolyte balance, generating, for example, antinatriuretic and antidiuretic effects in the kidney, and consequently promotes release of the peptide vasopressin from the pituitary, on the one hand, and of aldosterone from the adrenal glomerulosa, on the other. All these effects play an important role in blood pressure regulation.
  • Angiotensin II interacts with specific receptors on the surface of the target cells. Success has by now been achieved in identifying receptor subtypes which are, for example, designated AT 1 receptors and AT 2 receptors. Recently, considerable efforts have been made to identify the substances which bind selectively to the AT 1 receptor. These active compounds are called angiotensin II antagonists or angiotensin II receptor blockers. As a consequence of the inhibition of the AT 1 receptor, these antagonists can, for example, be employed as antihypertensives or for treating congestive heart failure.
  • Ischaemic heart disease is the leading cause of death in industrialised countries.
  • the management of ischaemic heart disease essentially relies upon one of three strategies, comprising medical therapy, percutaneous transluminal procedures, such as coronary angioplasty and atherectomy, and coronary artery bypass grafting.
  • medical therapy remains the mainstay of anti-ischaemic therapy, many patients undergo additional, invasive therapy in an attempt to restore coronary blood flow.
  • MI Acute m yocardial i nfarction
  • Troponin T as a serum marker for MI is disclosed in V. V. Murthy and A. Karmen, J. Clin. Labor. Analys. 11: 125-128 (1997).
  • Typical ECG changes include evolving ST-segment or T-wave changes in two or more contiguous ECG leads, the development of new pathological Q/QS waves in two or more contiguous ECG leads, or the development of new left bundle branch block.
  • Survivors of acute MI are at moderate risk of recurrent infarction or cardiac death. Morbidity and mortality following an MI may be related to arrhythmias, to left ventricular dysfunction, and to recurrent MI.
  • Aspirin is used for secondary prevention in survivors of MI. Because aspirin had a significant protective effect in secondary prevention of vascular disease, the possible benefit of aspirin in primary prevention has also been tested. However, several studies have shown that only a limited percent of the population at risk really benefits from aspirin therapy. For primary prevention, for instance, aspirin should be considered only in men over the age of 50 with uncontrolled risk factors for the development of coronary events (Cairns J A, Lewis H D, Meade T W, Sutton G C, Theroux P. Antithrombotic agents in coronary artery disease. Chest 108 (supp4):3805, 1995).
  • primary prevention is the protection of health by personal and community-wide effects such as preserving good nutritional status, physical fitness and emotional well-being.
  • Primary prevention includes general health promotion and specific protective measures. It can also be defined as prevention of disease by altering susceptibility or reducing exposure for susceptible individuals. It is difficult to see how the administration of the angiotensin II antagonist losartan, for example, could be viewed as a measure to promote general health. It would imply administering an angiotensin II antagonist to the population at large, with the—extremely difficult to quantify—aim of avoiding a MI in part of that population.
  • Secondary prevention includes all measures available to individuals and populations for the early detection and prompt and effective intervention to correct departures from good health. In short, secondary prevention aims to reduce prevalence by shortening the duration.
  • ACE inhibitors have been used for secondary prevention in patients with post-MI, i.e. the use of ACE inhibitors when the patient suffers his/her FIRST MI can PREVENT further complications related to the initial event and thus improve survival.
  • AT 1 receptor antagonists provides in addition to the ACE inhibitors a new, more specific pharmacological tool to inhibit the renin-angiotensin cascade.
  • AT 1 receptor antagonists there are distinguishing features between AT 1 receptor antagonists and ACE inhibitors.
  • One is manifested by the concomitant potentiation of bradykinin produced by ACE inhibitors, since the kinase II and converting enzyme are one in the same.
  • the bradykinin related mechanism mediated through nitric oxide, prostaglandins, and endothelially derived hyper-polaring factor may be responsible for a different clinical effect of ACE inhibitors.
  • the effect of the AT 2 is not yet clear, as an inhibition of the AT 1 receptor leads to an incease of AT 2 .
  • Treatment implies implementing measures—changes in life-style, specific drugs such as antibiotics—which can modify the course of the disease (such as administering angiotensin converting enzyme inhibitors to patients with congestive heart failure in order to prolong their survival) and/or make the cause of the disease disappear.
  • antibiotics which can modify the course of the disease (such as administering angiotensin converting enzyme inhibitors to patients with congestive heart failure in order to prolong their survival) and/or make the cause of the disease disappear.
  • the patient can be treated with a drug which is expected to—decrease his/her mortality rate and—improve short- and long-term prognosis.
  • the rationale behind TREATING patients with an acute MI e.g. with the angiotensin II antagonist valsartan rests on preliminary preclinical scientific works which have shown that the administration of the compound does reduce the size of the MI, which, through its impact on left ventricular function, is one of the main determinants of survival.
  • the aim of the present invention is to provide a therapeutic approach for the treatment of acute MI and for the secondary prevention of acute MI.
  • angiotensin II receptor antagonists may be used for the treatment of acute MI and for the secondary prevention of acute MI.
  • the beneficial effect can be demonstrated by carrying out study comparing the efficacy of short-term or long-term application of a therapeutically effective angiotensin II antagonist to an established (recognised) therapy for this indication.
  • Corresponding studies are, for example, designed by evaluating two parallel groups of patients in prospective multinational, multicenter, double-blind, randomized, actively controlled clinical study having statistical relevance.
  • the first group comprises a population having a high risk of be susceptible to acute MI, e.g.
  • angiotensin II receptor antagonist exhibiting corresponding risk factors, like stress, high blood pressure diabetes, high body weight, family history, etc., which is treated with a therapeutically effective amount of an angiotensin II receptor antagonist, while the second group likewise comprises population having likewise a high risk of being susceptible to acute MI, however, treated with an angiotensin converting enzyme inhibitor, such as captopril.
  • the duration of such studies is variable and depends upon achieving a pre-specified number or primary endpoints. For example, such study duration may normally be at least 4 years including 18 months of enrollment, but may also be shorter. All data and safety are monitored by an independent monitoring board performing analyses at timepoints during the study.
  • an angiontensin II receptor antagonist can be used for the treatment of acute MI and for the secondary prevention of acute MI.
  • the invention provides a pharmaceutical preparation treatment of acute MI and for the secondary prevention of acute MI, which comprises an AT 1 receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments (active ingredients) of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc., for the treatment of acute MI, especially in the population at large (including high risk patients).
  • an AT 1 receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments (active ingredients) of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc.
  • Preferred other accepted treatments (active ingredients) of the acute and chronic phases of MI to be used in a combination with AT 1 receptor antagonists are ACE inhibitors, including but not limited to a member of the group consisting of alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril.
  • ACE inhibitors including but not limited to a member of the group consisting of alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enapril
  • a combined pharmaceutical preparation for simultaneous, separate or sequential use for the treatment of acute MI and also for the secondary prevention of acute MI comprising an AT 1 receptor blocker and an other accepted treatment of the acute and chronic phases of MI which may be used for such treatment, e.g. selected from the group consisting of an ACE inhibitor, a beta-blocker and aspirin, in each case in a unit dosage form, in admixture with a pharmaceutically acceptable carrier.
  • a pharmaceutical combination for the treatment of acute MI and for the secondary prevention of acute MI comprising an AT 1 receptor blocker and an other accepted active ingredient for the treatment of acute and chronic phases of myocardial infarction, e.g. selected from the group consisting of an ACE inhibitor, a beta-blocker and aspirin, or, in each case, a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.
  • an AT 1 receptor blocker e.g. selected from the group consisting of an ACE inhibitor, a beta-blocker and aspirin, or, in each case, a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.
  • lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.
  • the invention also provides the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc., for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI, especially in the population at large (including high risk patients).
  • an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof either alone or in combination with other accepted treatments of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc.
  • the invention furthermore provides a method for the treatment of acute MI and for the secondary prevention of acute MI, especially in the population at large (including high risk patients) which comprises administering to a warm-blooded animal, including human, a therapeutically effective amount of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc.
  • the invention also provides the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc., for the treatment of acute MI, especially in the population at large (including high risk patients).
  • an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof either alone or in combination with other accepted treatments of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc.
  • Angiotensin II receptor antagonists include compounds having differing structural features. For example, mention may be made of the compounds which are listed in the European Patent Application having the publication No. 443983 (EP 443983), in particular in the compound claims and the final products of the working examples, the subject-matter of which claims is hereby incorporated into the present application by reference to this publication.
  • Angiotensin II receptor antagonists which, for example, possess at least one basic centre can form acid addition salts. These are formed, for example, using strong inorganic acids, such as mineral acids, e.g. sulfuric acid, a phosphoric acid or a hydrohalic acid, using strong organic carboxylic acids, such as C 1 -C 4 alkanecarboxylic acids which are unsubstituted or substituted, for example, by halogen, e.g. acetic acid, such as saturated or unsaturated dicarboxylic acids, e.g. oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, e.g.
  • strong inorganic acids such as mineral acids, e.g. sulfuric acid, a phosphoric acid or a hydrohalic acid
  • strong organic carboxylic acids such as C 1 -C 4 alkanecarboxylic acids which are unsubstituted
  • ascorbic, glycolic, lactic, malic, tartaric or citric acid such as amino acids, e.g. aspartic or glutamic acid, or such as benzoic acid, or using organic sulfonic acids, such as C 1 -C 4 alkanesulfonic acids or arylsulfonic acids which are unsubstituted or substituted, for example, by halogen, e.g. methanesulfonic acid or p-toluenesulfonic acid.
  • suitable salts with bases are metal salts, such as alkali metal or alkaline earth metal salts, e.g.
  • sodium, potassium or magnesium salts or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkyl amine, e.g. ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropyl-amines, or a mono-, di- or tri-hydroxy lower alkyl amine, e.g. mono-, di- or tri-ethanolamine.
  • corresponding internal salts can be formed.
  • compositions are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances.
  • the pharmaceutical preparations consist of from about 0.1% to 100%, preferably of from about 1% to about 80%, of the active compound.
  • Pharmaceutical preparations for enteral or parenteral, and also for ocular, administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner which is known per se, for example using conventional mixing, granulation, coating, solubulizing or lyophilizing processes.
  • compositions for oral use can be obtained by combining the active compound with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.
  • the dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition. Normally, in the case of oral administration, an approximate daily dose of from about 10 mg to about 360 mg, for example in the case of Valsartan e.g. of about 40 mg, 80 mg, 160 mg or 320 mg, is to be estimated for a patient.
  • a preferred angiotensin II receptor antagonist is valsartan.
  • Valsartan will be supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 20 to about 320 mg, of valsartan which may be applied to patients in the need to be treated for the secondary prevention of post-MI.
  • the application of the active ingredient may occur up to three times a day, starting e.g. with a daily dose of 20 mg or 40 mg of valsartan, increasing via 80 mg daily and further to 160 mg daily up to 320 mg daily.
  • valsartan is applied twice a day with a dose of 80 mg or 160 mg, respectively, each.
  • Corresponding doses may be taken, for example, in the morning, at mid-day or in the evening.
  • Preferred is b.i.d. administration.
  • Preferred dosages for pharmaceutical combinations are therapeutically effective dosages, especially those which are commercially available. Especially preferred are low dose combinations.
  • preferred dosage unit forms of ACE inhibitors are, for example, tablets or capsules comprising e.g. from about 5 mg to about 20 mg, preferably 5 mg, 10 mg or 20 mg, of benazepril; from about 6.5 mg to 100 mg, preferably 6.25 mg, 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg, of captopril; from about 2.5 mg to about 20 mg, preferably 2.5 mg, 5 mg, 10 mg or 20 mg, of enalapril; from about 10 mg to about 20 mg, preferably 10 mg or 20 mg, of fosinopril; from about 2.5 mg to about 4 mg, preferably 2 mg or 4 mg, of perindopril; from about 5 mg to about 20 mg, preferably 5 mg, 10 mg or 20 mg, of quinapril; or from about 1.25 mg to about 5 mg, preferably 1.25 mg, 2.5 mg,
  • the film-coated tablet is manufactured e.g. as follows:
  • a mixture of valsartan, microcrystalline cellulose, crospovidone, part of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200, silicon dioxide and magnesium stearate is premixed in a diffusion mixer and then sieve through a screening mill.
  • the resulting mixture is again pre-mixed in a diffusion mixer, compacted in a roller compacter and then sieve through a screening mill.
  • the rest of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200 are added and the final blend is made in a diffusion mixer.
  • the whole mixture is compressed in a rotary tabletting machine and the tabletts are coated with a film by using Diolack pale red in a perforated pan.
  • Composition Components Per Unit (mg) Standards Granulation Valsartan [ active ingredient] 160.00 Microcrystalline cellulose/ 108.00 NF, Ph. Eur Avicel PH 102 Crospovidone 40.00 NF, Ph. Eur Colloidal anhydrous silica/ 1.50 Ph. Eur/ colloidal silicon dioxide/Aerosil 200 NF Magnesium stearate 5.00 NF, Ph. Eur Blending Colloidal anhydrous silica/ 1.50 Ph. Eur/ colloidal silicon dioxide/Aerosil 200 NF Magnesium stearate 4.00 NF, Ph. Eur Coating Opadry Light Brown 00F33172 10.00 Total tablet mass 330.00
  • the film-coated tablet is manufactured e.g. as described in Formulation Example 1.
  • the film-coated tablet is manufactured e.g. as described in Formulation Example 1.
  • the tablet is manufactured e.g. as follows:
  • Valsartan and microcrystalline cellulose are spray-granulated in a fluidised bed granulator with a granulating solution consisting of povidone and sodium lauryl sulphate dissolved in purified water.
  • the granulate obtained is dried in a fluidised bed dryer.
  • the dried granulate is milled together with crospovidone and magnesium stearate.
  • the mass is then blended in a conical screw type mixer for approximately 10 minutes.
  • the empty hard gelatin capsules are filled with the blended bulk granules under controlled temperature and humidity conditions.
  • the filed capsules are dedusted, visually inspected, weightchecked and quarantied until by Quality assurance department.
  • the formulation is manufactured e.g. as described in Formulation Example 4.
  • a hard gelatin capsule comprising as active ingredient e.g. (S)—N—(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2′(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine, can be formulated, for example, as follows:
  • Components (1) and (2) are granulated with a solution of components (3) and (4) in water.
  • the components (5) and (6) are added to the dry granulate and the mixture is filled into size 1 hard gelatin capsules.

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

The invention relates to the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI.

Description

This application is a division of U.S. application Ser. No. 10/376,049, filed on Feb. 27, 2003, which is a division of U.S. application Ser. No. 09/915,048, filed on Jul. 25, 2001, now U.S. Pat. No. 6,544,968, which is a continuation of International Application No. PCT/EP00/00525, filed Jan. 24, 2000, which is a continuation of U.S. application Ser. No. 09/468,664, filed Dec. 21, 1999, now abandoned.
The enzyme cascade of the renin-angiotensin system (RAS) comprises a series of biochemical events and, as is well known, there are a variety of approaches for using regulatory intervention to open up treatment possibilities, for example treatment of hypertension.
Angiotensinogen, an α2-macroglycoprotein, is cleaved by the enzyme renin into the decapeptide angiotensin I, which is itself only very slightly active biologically. In the next step of the cascade, two further amino acids are cleaved off by the action of the enzyme angiotensin converting enzyme (ACE), which is mainly bound in the endothelium, with the formation of angiotensin II. The latter is regarded as being one of the most powerful natural vasconstrictors.
The vasoconstrictive effects of angiotensin II are brought about by its action on the smooth muscle cells, and by stimulating formation of the adrenergic hormones adrenaline and noradrenaline and by increasing the activity of the sympathetic nervous system due to the formation of noradrenaline. In addition angiotensin II affects the electrolyte balance, generating, for example, antinatriuretic and antidiuretic effects in the kidney, and consequently promotes release of the peptide vasopressin from the pituitary, on the one hand, and of aldosterone from the adrenal glomerulosa, on the other. All these effects play an important role in blood pressure regulation.
Angiotensin II interacts with specific receptors on the surface of the target cells. Success has by now been achieved in identifying receptor subtypes which are, for example, designated AT1 receptors and AT2 receptors. Recently, considerable efforts have been made to identify the substances which bind selectively to the AT1 receptor. These active compounds are called angiotensin II antagonists or angiotensin II receptor blockers. As a consequence of the inhibition of the AT1 receptor, these antagonists can, for example, be employed as antihypertensives or for treating congestive heart failure.
Ischaemic Heart Disease—Acute Myocardial Infarction
Ischaemic heart disease is the leading cause of death in industrialised countries. The management of ischaemic heart disease essentially relies upon one of three strategies, comprising medical therapy, percutaneous transluminal procedures, such as coronary angioplasty and atherectomy, and coronary artery bypass grafting. Although medical treatment remains the mainstay of anti-ischaemic therapy, many patients undergo additional, invasive therapy in an attempt to restore coronary blood flow. However, there is increasingly intense discussion regarding not only the relative merits of these therapeutic approaches but also the point within the management of ischaemic heart disease at which they should be applied and the type of patient for which each is more appropriate.
Acute myocardial infarction (MI) strikes the majority of sufferers without prior warning and in the absence of clinically detectable predisposing risk factors (Braunwald E. Heart Disease—a Textbook of Cardiovascular Medicine. 1997). When patients come to the intensive unit in a hospital showing symptoms of acute MI, the diagnosis for acute MI requires that the patients must have
  • (1) an increase in the plasma concentration of cardiac enzymes and
  • (2) either a typical clinical presentation and/or typical ECG changes.
Either of the following parameters will fulfill the requirement for an increase in cardiac enzymes:
    • Total creatine-kinase (CK) at least 2 times the upper limit of the normal range, or
    • CK-MB (muscle-brain) above the upper limit of the normal range and at least 5% of the normal CK.
If total CK or CK-MB is not available, the following will be accepted in the fulfillment of the criteria for acute MI:
    • Troponin T at least 3 times the upper limit of the normal range;
    • Troponin I at least 3 times the upper limit of the normal range.
The use of Troponin T as a serum marker for MI is disclosed in V. V. Murthy and A. Karmen, J. Clin. Labor. Analys. 11: 125-128 (1997). The analytical performance and clinical utility if a sensitive immunoassay for determination of cardiac Troponin I can be taken from E. Davies et al. Clin. Biochem. 30: 479-490 (1997).
Typical ECG changes include evolving ST-segment or T-wave changes in two or more contiguous ECG leads, the development of new pathological Q/QS waves in two or more contiguous ECG leads, or the development of new left bundle branch block.
Secondary prevention, namely the implementation of therapy to postpone further coronary events thus continues to remain the major goal of prophylactic drug therapy in these patients.
Survivors of acute MI are at moderate risk of recurrent infarction or cardiac death. Morbidity and mortality following an MI may be related to arrhythmias, to left ventricular dysfunction, and to recurrent MI. Aspirin is used for secondary prevention in survivors of MI. Because aspirin had a significant protective effect in secondary prevention of vascular disease, the possible benefit of aspirin in primary prevention has also been tested. However, several studies have shown that only a limited percent of the population at risk really benefits from aspirin therapy. For primary prevention, for instance, aspirin should be considered only in men over the age of 50 with uncontrolled risk factors for the development of coronary events (Cairns J A, Lewis H D, Meade T W, Sutton G C, Theroux P. Antithrombotic agents in coronary artery disease. Chest 108 (supp4):3805, 1995).
Secondary Prevention of Acute Myocardial Infarction
The concept of secondary prevention of reinfarction and death after recovery from an MI has been actively investigated for several decades. Problems in proving the efficacy of various interventions have been related both to the ineffectiveness of certain strategies and to the difficulty in proving a benefit as mortality and morbidity have improved following MI. Although secondary prevention drug trials generally have tested one form of therapy against placebo in an attempt to demonstrate a benefit of that therapy, the physician must remember that disciplined clinical care of the individual patients is far more important than rote use of an agent found beneficial in the latest drug trial.
Primary & Secondary Prevention—Epidemiological
From an epidemiological standpoint, primary prevention is the protection of health by personal and community-wide effects such as preserving good nutritional status, physical fitness and emotional well-being. Primary prevention includes general health promotion and specific protective measures. It can also be defined as prevention of disease by altering susceptibility or reducing exposure for susceptible individuals. It is difficult to see how the administration of the angiotensin II antagonist losartan, for example, could be viewed as a measure to promote general health. It would imply administering an angiotensin II antagonist to the population at large, with the—extremely difficult to quantify—aim of avoiding a MI in part of that population. Secondary prevention, on the other hand, includes all measures available to individuals and populations for the early detection and prompt and effective intervention to correct departures from good health. In short, secondary prevention aims to reduce prevalence by shortening the duration.
ACE inhibitors have been used for secondary prevention in patients with post-MI, i.e. the use of ACE inhibitors when the patient suffers his/her FIRST MI can PREVENT further complications related to the initial event and thus improve survival.
The development of the AT1 receptor antagonists provides in addition to the ACE inhibitors a new, more specific pharmacological tool to inhibit the renin-angiotensin cascade. However, there are distinguishing features between AT1 receptor antagonists and ACE inhibitors. One is manifested by the concomitant potentiation of bradykinin produced by ACE inhibitors, since the kinase II and converting enzyme are one in the same. The bradykinin related mechanism mediated through nitric oxide, prostaglandins, and endothelially derived hyper-polaring factor may be responsible for a different clinical effect of ACE inhibitors. Furthermore, the effect of the AT2 is not yet clear, as an inhibition of the AT1 receptor leads to an incease of AT2.
Treatment, on the other hand, implies implementing measures—changes in life-style, specific drugs such as antibiotics—which can modify the course of the disease (such as administering angiotensin converting enzyme inhibitors to patients with congestive heart failure in order to prolong their survival) and/or make the cause of the disease disappear. Once the acute MI has been diagnosed, the patient can be treated with a drug which is expected to—decrease his/her mortality rate and—improve short- and long-term prognosis. The rationale behind TREATING patients with an acute MI e.g. with the angiotensin II antagonist valsartan rests on preliminary preclinical scientific works which have shown that the administration of the compound does reduce the size of the MI, which, through its impact on left ventricular function, is one of the main determinants of survival.
The aim of the present invention is to provide a therapeutic approach for the treatment of acute MI and for the secondary prevention of acute MI.
It has surprisingly been found that angiotensin II receptor antagonists may be used for the treatment of acute MI and for the secondary prevention of acute MI.
This beneficial effect can be demonstrated by carrying out study comparing the efficacy of short-term or long-term application of a therapeutically effective angiotensin II antagonist to an established (recognised) therapy for this indication. Corresponding studies are, for example, designed by evaluating two parallel groups of patients in prospective multinational, multicenter, double-blind, randomized, actively controlled clinical study having statistical relevance. The first group comprises a population having a high risk of be susceptible to acute MI, e.g. exhibiting corresponding risk factors, like stress, high blood pressure diabetes, high body weight, family history, etc., which is treated with a therapeutically effective amount of an angiotensin II receptor antagonist, while the second group likewise comprises population having likewise a high risk of being susceptible to acute MI, however, treated with an angiotensin converting enzyme inhibitor, such as captopril. The duration of such studies is variable and depends upon achieving a pre-specified number or primary endpoints. For example, such study duration may normally be at least 4 years including 18 months of enrollment, but may also be shorter. All data and safety are monitored by an independent monitoring board performing analyses at timepoints during the study.
In order to fulfill the criteria of acute MI (cf. above),
  • (1) all patients must have an increase in the plasma concentration of cardiac enzymes, such as the total creatine-kinase (CK) to at least twice the upper limit of the normal range or the CK-MB is above the upper limit of the normal range and at least 5% of the total CK, and
  • (2) all patients must have either a typical clinical presentation and/or typical ECG changes, e.g. including evolving ST-segment or T-wave changes in two or more contiguous ECG leads or include the development of the new bundle branch block.
It can thus be proven that a long-term application with an angiontensin II receptor antagonist can be used for the treatment of acute MI and for the secondary prevention of acute MI.
The invention provides a pharmaceutical preparation treatment of acute MI and for the secondary prevention of acute MI, which comprises an AT1 receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments (active ingredients) of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc., for the treatment of acute MI, especially in the population at large (including high risk patients).
Preferred other accepted treatments (active ingredients) of the acute and chronic phases of MI to be used in a combination with AT1 receptor antagonists are ACE inhibitors, including but not limited to a member of the group consisting of alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril.
A combined pharmaceutical preparation for simultaneous, separate or sequential use for the treatment of acute MI and also for the secondary prevention of acute MI comprising an AT1 receptor blocker and an other accepted treatment of the acute and chronic phases of MI which may be used for such treatment, e.g. selected from the group consisting of an ACE inhibitor, a beta-blocker and aspirin, in each case in a unit dosage form, in admixture with a pharmaceutically acceptable carrier.
A pharmaceutical combination for the treatment of acute MI and for the secondary prevention of acute MI comprising an AT1 receptor blocker and an other accepted active ingredient for the treatment of acute and chronic phases of myocardial infarction, e.g. selected from the group consisting of an ACE inhibitor, a beta-blocker and aspirin, or, in each case, a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.
All the more surprising is the experimental finding that the combined administration results not only in a beneficial, especially a complementary and synergistic, therapeutic effect but also in additional benefits resulting from combined treatment such as a surprising prolongation of efficacy, a broader variety of therapeutic treatment and surprising beneficial effects on diseases and conditions associated with acute MI.
Further benefits are that lower doses of the individual drugs to be combined according to the present invention can be used to reduce the dosage, for example, that the dosages need not only often be smaller but are also applied less frequently, or can be used in order to diminish the incidence of side effects. This is in accordance with the desires and requirements of the patients to be treated.
The invention also provides the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc., for the manufacture of a medicament for the treatment of acute MI and for the secondary prevention of acute MI, especially in the population at large (including high risk patients).
The invention furthermore provides a method for the treatment of acute MI and for the secondary prevention of acute MI, especially in the population at large (including high risk patients) which comprises administering to a warm-blooded animal, including human, a therapeutically effective amount of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc.
The invention also provides the use of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof, either alone or in combination with other accepted treatments of the acute and chronic phases of MI, such as, for instance, ACEIs, beta blockers, aspirin, etc., for the treatment of acute MI, especially in the population at large (including high risk patients).
Angiotensin II receptor antagonists include compounds having differing structural features. For example, mention may be made of the compounds which are listed in the European Patent Application having the publication No. 443983 (EP 443983), in particular in the compound claims and the final products of the working examples, the subject-matter of which claims is hereby incorporated into the present application by reference to this publication.
Preference is given to (S)—N-(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N—[2′(1H-tetrazol-5-yl)biphenyl-4-ylmethyl]amine [Valsartan] of the formula
Figure US07560446-20090714-C00001
and its pharmaceutically utilizable salts.
Furthermore, the compounds which are listed in European Patent Application having the publication No. 253310 (EP 253310), in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [Losartan] of the following formula
Figure US07560446-20090714-C00002
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in the European Patent Application having the publication No. 403159 (EP 403159), in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [Eprosartan] of the following formula
Figure US07560446-20090714-C00003
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in the PCT Patent Application having the publication No. WO 91/14679, in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [Irbesartan] of the following formula
Figure US07560446-20090714-C00004
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in the European Patent Application having the publication No. EP 420237 (EP 420237), in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [E-1477] of the following formula
Figure US07560446-20090714-C00005
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in the European Patent Application having the publication No. 502314 (EP 502314), in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [Telmisartan] of the following formula
Figure US07560446-20090714-C00006
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in the European Patent Application having the publication No. 459136 (EP 459136), in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [Candesartan] of the following formula
Figure US07560446-20090714-C00007
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in European Patent Application having the publication No. 504888 (EP 504888), in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [SC-52458] of the following formula
Figure US07560446-20090714-C00008
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in the European Patent Application having the publication No. 514198 (EP 514198), in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [Saprisartan] of the following formula
Figure US07560446-20090714-C00009
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in the European Patent Application having the publication No. 475206 (EP 475206), in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound of the following formula
Figure US07560446-20090714-C00010
and its pharmaceutically utilizable salts.
Furthermore, the compounds listed in the PCT Patent Application having the publication No. WO 93/20816, in particular in the compound claims and the final products of the working examples, are hereby incorporated into the present application by reference to this publication.
Preference is given to the compound [ZD-8731] of the following formula
Figure US07560446-20090714-C00011
and its pharmaceutically utilizable salts.
Angiotensin II receptor antagonists which, for example, possess at least one basic centre can form acid addition salts. These are formed, for example, using strong inorganic acids, such as mineral acids, e.g. sulfuric acid, a phosphoric acid or a hydrohalic acid, using strong organic carboxylic acids, such as C1-C4alkanecarboxylic acids which are unsubstituted or substituted, for example, by halogen, e.g. acetic acid, such as saturated or unsaturated dicarboxylic acids, e.g. oxalic, malonic, succinic, maleic, fumaric, phthalic or terephthalic acid, such as hydroxycarboxylic acids, e.g. ascorbic, glycolic, lactic, malic, tartaric or citric acid, such as amino acids, e.g. aspartic or glutamic acid, or such as benzoic acid, or using organic sulfonic acids, such as C1-C4alkanesulfonic acids or arylsulfonic acids which are unsubstituted or substituted, for example, by halogen, e.g. methanesulfonic acid or p-toluenesulfonic acid. Examples of suitable salts with bases are metal salts, such as alkali metal or alkaline earth metal salts, e.g. sodium, potassium or magnesium salts, or salts with ammonia or an organic amine, such as morpholine, thiomorpholine, piperidine, pyrrolidine, a mono-, di- or tri-lower alkyl amine, e.g. ethyl-, tert-butyl-, diethyl-, diisopropyl-, triethyl-, tributyl- or dimethylpropyl-amines, or a mono-, di- or tri-hydroxy lower alkyl amine, e.g. mono-, di- or tri-ethanolamine. Furthermore, corresponding internal salts can be formed.
Pharmaceutical preparations are for enteral, such as oral, and also rectal or parenteral, administration to homeotherms, with the preparations comprising the pharmacological active compound either alone or together with customary pharmaceutical auxiliary substances. For example, the pharmaceutical preparations consist of from about 0.1% to 100%, preferably of from about 1% to about 80%, of the active compound. Pharmaceutical preparations for enteral or parenteral, and also for ocular, administration are, for example, in unit dose forms, such as coated tablets, tablets, capsules or suppositories and also ampoules. These are prepared in a manner which is known per se, for example using conventional mixing, granulation, coating, solubulizing or lyophilizing processes. Thus, pharmaceutical preparations for oral use can be obtained by combining the active compound with solid excipients, if desired granulating a mixture which has been obtained, and, if required or necessary, processing the mixture or granulate into tablets or coated tablet cores after having added suitable auxiliary substances.
The dosage of the active compound can depend on a variety of factors, such as mode of administration, homeothermic species, age and/or individual condition. Normally, in the case of oral administration, an approximate daily dose of from about 10 mg to about 360 mg, for example in the case of Valsartan e.g. of about 40 mg, 80 mg, 160 mg or 320 mg, is to be estimated for a patient.
A preferred angiotensin II receptor antagonist is valsartan. Valsartan will be supplied in the form of suitable dosage unit form, for example, a capsule or tablet, and comprising a therapeutically effective amount, e.g. from about 20 to about 320 mg, of valsartan which may be applied to patients in the need to be treated for the secondary prevention of post-MI. The application of the active ingredient may occur up to three times a day, starting e.g. with a daily dose of 20 mg or 40 mg of valsartan, increasing via 80 mg daily and further to 160 mg daily up to 320 mg daily. Preferably, valsartan is applied twice a day with a dose of 80 mg or 160 mg, respectively, each. Corresponding doses may be taken, for example, in the morning, at mid-day or in the evening. Preferred is b.i.d. administration.
Preferred dosages for pharmaceutical combinations are therapeutically effective dosages, especially those which are commercially available. Especially preferred are low dose combinations. In case of ACE inhibitors, preferred dosage unit forms of ACE inhibitors are, for example, tablets or capsules comprising e.g. from about 5 mg to about 20 mg, preferably 5 mg, 10 mg or 20 mg, of benazepril; from about 6.5 mg to 100 mg, preferably 6.25 mg, 12.5 mg, 25 mg, 50 mg, 75 mg or 100 mg, of captopril; from about 2.5 mg to about 20 mg, preferably 2.5 mg, 5 mg, 10 mg or 20 mg, of enalapril; from about 10 mg to about 20 mg, preferably 10 mg or 20 mg, of fosinopril; from about 2.5 mg to about 4 mg, preferably 2 mg or 4 mg, of perindopril; from about 5 mg to about 20 mg, preferably 5 mg, 10 mg or 20 mg, of quinapril; or from about 1.25 mg to about 5 mg, preferably 1.25 mg, 2.5 mg, or 5 mg, of ramipril. Preferred is t.i.d. administration.
The following examples illustrate the above-described invention; however, it is not intended to restrict the scope of this invention in any manner.
FORMULATION EXAMPLE 1 Film-Coated Tablets
Composition
Components Per Unit (mg) Standards
Granulation
Valsartan [=active ingredient] 80.00
Microcrystalline cellulose/ 54.00 NF, Ph. Eur
Avicel PH 102
Crospovidone 20.00 NF, Ph. Eur
Colloidal anhydrous silica/ 0.75 Ph. Eur/
colloidal silicon dioxide/Aerosil 200 NF
Magnesium stearate 2.5 NF, Ph. Eur
Blending
Colloidal anhydrous silica/ 0.75 Ph. Eur/
colloidal silicon dioxide/Aerosil 200 NF
Magnesium stearate 2.00 NF, Ph. Eur
Coating
Purified water*) —
DIOLACK pale red 00F34899 7.00
Total tablet mass 167.00
*)Removed during processing.
The film-coated tablet is manufactured e.g. as follows:
A mixture of valsartan, microcrystalline cellulose, crospovidone, part of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200, silicon dioxide and magnesium stearate is premixed in a diffusion mixer and then sieve through a screening mill. The resulting mixture is again pre-mixed in a diffusion mixer, compacted in a roller compacter and then sieve through a screening mill. To the resulting mixture, the rest of the colloidal anhydrous silica/colloidal silicon dioxide/Aerosile 200 are added and the final blend is made in a diffusion mixer. The whole mixture is compressed in a rotary tabletting machine and the tabletts are coated with a film by using Diolack pale red in a perforated pan.
FORMULATION EXAMPLE 2 Film-coated Tablets
Composition
Components Per Unit (mg) Standards
Granulation
Valsartan [=active ingredient] 160.00
Microcrystalline cellulose/ 108.00 NF, Ph. Eur
Avicel PH 102
Crospovidone 40.00 NF, Ph. Eur
Colloidal anhydrous silica/ 1.50 Ph. Eur/
colloidal silicon dioxide/Aerosil 200 NF
Magnesium stearate 5.00 NF, Ph. Eur
Blending
Colloidal anhydrous silica/ 1.50 Ph. Eur/
colloidal silicon dioxide/Aerosil 200 NF
Magnesium stearate 4.00 NF, Ph. Eur
Coating
Opadry Light Brown 00F33172 10.00
Total tablet mass 330.00
The film-coated tablet is manufactured e.g. as described in Formulation Example 1.
FORMULATION EXAMPLE 3 Film-coated Tablets
Composition Per
Components Unit (mg) Standards
Core: Internal phase
Valsartan 40.00
[=active ingredient]
Silica, colloidal anhydrous 1.00 Ph. Eur, USP/NF
(Colloidal silicon dioxide)
[=Glidant]
Magnesium stearate 2.00 USP/NF
[=Lubricant]
Crospovidone 20.00 Ph. Eur
[Disintegrant]
Microcrystalline cellulose 124.00 USP/NF
[=Binding agent]
External phase
Silica, colloidal anhydrous, 1.00 Ph. Eur, USP/NF
(Colloidal silicon dioxide)
[=Glidant]
Magnesium stearate 2.00 USP/NF
[Lubricant]
Film coating
Opadry ® brown OOF 16711*) 9.40
Purified Water**) —
Total tablet mass 199.44
*)The composition of the Opadry ® brown OOF16711 coloring agent is tabulated below.
**)Removed during processing
Opadry® Composition
Approximate %
Ingredient Composition
Iron oxide, black (C.I. No. 77499, E 172) 0.50
Iron oxide, brown (C.I. No. 77499, E 172 0.50
Iron oxide, red (C.I. No. 77491, E 172) 0.50
Iron oxide, yellow (C.I. No. 77492, E 172) 0.50
Macrogolum (Ph. Eur) 4.00
Titanium dioxide (C.I. No. 77891, E 171) 14.00
Hypromellose (Ph. Eur) 80.00
The film-coated tablet is manufactured e.g. as described in Formulation Example 1.
FORMULATION EXAMPLE 4 Capsules
Composition
Components Per Unit (mg)
Valsartan [=active ingredient] 80.00
Microcrystalline cellulose 25.10
Crospovidone 13.00
Povidone 12.50
Magnesium stearate 1.30
Sodium lauryl sulphate 0.60
Shell
Iron oxide, red 0.123
(C.I. No. 77491, EC No. E 172)
Iron oxide, yellow 0.123
(C.I. No. 77492, EC No. E 172)
Iron oxide, black 0.245
(C.I. No. 77499, EC No. E 172)
Titanium dioxide 1.540
Gelatin 74.969
Total tablet mass 209.50
The tablet is manufactured e.g. as follows:
Granulation/Drying
Valsartan and microcrystalline cellulose are spray-granulated in a fluidised bed granulator with a granulating solution consisting of povidone and sodium lauryl sulphate dissolved in purified water. The granulate obtained is dried in a fluidised bed dryer.
Milling/Blending
The dried granulate is milled together with crospovidone and magnesium stearate. The mass is then blended in a conical screw type mixer for approximately 10 minutes.
Encapsulation
The empty hard gelatin capsules are filled with the blended bulk granules under controlled temperature and humidity conditions. The filed capsules are dedusted, visually inspected, weightchecked and quarantied until by Quality assurance department.
FORMULATION EXAMPLE 5 Capsules
Composition
Components Per Unit (mg)
Valsartan [=active ingredient] 160.00
Microcrystalline cellulose 50.20
Crospovidone 26.00
Povidone 25.00
Magnesium stearate 2.60
Sodium lauryl sulphate 1.20
Shell
Iron oxide, red 0.123
(C.I. No. 77491, EC No. E 172)
Iron oxide, yellow 0.123
(C.I. No. 77492, EC No. E 172)
Iron oxide, black 0.245
(C.I. No. 77499, EC No. E 172)
Titanium dioxide 1.540
Gelatin 74.969
Total tablet mass 342.00
The formulation is manufactured e.g. as described in Formulation Example 4.
FORMULATION EXAMPLE 6 Hard Gelatine Capsule
Composition
Components Per Unit (mg)
Valsartan [=active ingredient] 80.00
Sodium laurylsulphate 0.60
Magnesium stearate 1.30
Povidone 12.50
Crospovidone 13.00
Microcrystalline cellulose 21.10
Total tablet mass 130.00
FORMULATION EXAMPLE 7
A hard gelatin capsule, comprising as active ingredient e.g. (S)—N—(1-carboxy-2-methylprop-1-yl)-N-pentanoyl-N-[2′(1H-tetrazol-5-yl)biphenyl-4-yl-methyl]amine, can be formulated, for example, as follows:
Composition
  • (1) valsartan 80.0 mg
  • (2) microcrystalline cellulose 110.0 mg
  • (3) polyvidone K30 45.2 mg
  • (4) sodium lauryl sulfate 1.2 mg
  • (5) crospovidone 26.0 mg
  • (6) magnesium stearate 2.6 mg
Components (1) and (2) are granulated with a solution of components (3) and (4) in water. The components (5) and (6) are added to the dry granulate and the mixture is filled into size 1 hard gelatin capsules.

Claims (8)

1. A method for the secondary reduction of acute MI comprising administering a therapeutically effective amount of an angiotensin II receptor antagonist or a pharmaceutically acceptable salt thereof to a patient who is asymptomatic with respect to heart failure.
2. The method of claim 1 wherein the angiotensin II receptor antagonist is combined with a second active ingredient.
3. The method of claim 1 wherein the angiotensin II receptor antagonist is selected from the group consisting of:
Figure US07560446-20090714-C00012
Figure US07560446-20090714-C00013
Figure US07560446-20090714-C00014
or, in each case, of a pharmaceutically acceptable salt thereof.
4. The method of claim 1 wherein the angiotensin II receptor antagonist is valsartan of formula
Figure US07560446-20090714-C00015
or a pharmaceutically acceptable salt thereof.
5. The method of claim 2 wherein the second active ingredient is selected from the group consisting of alacepril, benazepril, benazeprilat, captopril, ceronapril, cilazapril, delapril, enalapril, enaprilat, fosinopril, imidapril, lisinopril, moveltopril, perindopril, quinapril, ramipril, spirapril, temocapril, and trandolapril.
6. The method of claim 5 wherein the second active ingredient is captopril.
7. A pharmaceutical combination composition for the secondary reduction of acute MI comprising an AT1 receptor blocker and a second active ingredient for the treatment of acute and chronic phases of myocardial infarction selected from the group consisting of an ACE inhibitor, a beta-blocker and aspirin, or, in each case, a pharmaceutically acceptable salt thereof in admixture with a pharmaceutically acceptable carrier.
8. The pharmaceutical combination composition of claim 7 for simultaneous, separate or sequential use.
US10/859,776 1999-01-26 2004-06-03 Use of angiotensin II receptor antagonists for treating acute myocardial infarction Expired - Fee Related US7560446B2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
US10/859,776 US7560446B2 (en) 1999-01-26 2004-06-03 Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
EP99810061.4 1999-01-26
EP99810061 1999-01-26
US46866499A 1999-12-21 1999-12-21
PCT/EP2000/000525 WO2000044378A1 (en) 1999-01-26 2000-01-24 Use of angiotensin ii receptor antagonists for treating acute myocardial infarction
US09/915,048 US6544968B2 (en) 1999-01-26 2001-07-25 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US10/376,049 US6767905B2 (en) 1999-01-26 2003-02-27 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US10/859,776 US7560446B2 (en) 1999-01-26 2004-06-03 Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
US10/376,049 Division US6767905B2 (en) 1999-01-26 2003-02-27 Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Publications (2)

Publication Number Publication Date
US20040224999A1 US20040224999A1 (en) 2004-11-11
US7560446B2 true US7560446B2 (en) 2009-07-14

Family

ID=8242650

Family Applications (3)

Application Number Title Priority Date Filing Date
US09/915,048 Expired - Fee Related US6544968B2 (en) 1999-01-26 2001-07-25 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US10/376,049 Expired - Fee Related US6767905B2 (en) 1999-01-26 2003-02-27 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US10/859,776 Expired - Fee Related US7560446B2 (en) 1999-01-26 2004-06-03 Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Family Applications Before (2)

Application Number Title Priority Date Filing Date
US09/915,048 Expired - Fee Related US6544968B2 (en) 1999-01-26 2001-07-25 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US10/376,049 Expired - Fee Related US6767905B2 (en) 1999-01-26 2003-02-27 Use of angiotensin II receptor antagonists for treating acute myocardial infarction

Country Status (3)

Country Link
US (3) US6544968B2 (en)
CN (1) CN101011390A (en)
ZA (1) ZA200106022B (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101011390A (en) * 1999-01-26 2007-08-08 诺瓦提斯公司 Use of angiotensin II receptor antagonists for treating acute myocardial infarction
AUPS236902A0 (en) * 2002-05-16 2002-06-13 Northern Sydney Area Health Service Composition and method for treating hypertension
WO2004002549A1 (en) * 2002-06-28 2004-01-08 Novartis Ag Use of organic compounds
ZA200804907B (en) * 2004-08-18 2009-04-29 Ace Aps Cosmetic and pharmaceutical compositions comprising ACE inhibitors and/or angiotensin II receptor antagonists
EP1865945A4 (en) * 2005-03-11 2008-05-21 Hong Kong Nitric Oxide Ltd Combination therapy for endothelial dysfunction, angina and diabetes
US20100028439A1 (en) * 2005-05-23 2010-02-04 Elan Pharma International Limited Nanoparticulate stabilized anti-hypertensive compositions
GB0700993D0 (en) * 2007-01-18 2007-02-28 Rainbow Engineering Services Novel compounds
RU2465900C2 (en) * 2007-04-17 2012-11-10 Рациофарм Гмбх Irbesartan-containing pharmaceutical compositions
WO2018002673A1 (en) 2016-07-01 2018-01-04 N4 Pharma Uk Limited Novel formulations of angiotensin ii receptor antagonists

Citations (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253310A2 (en) 1986-07-11 1988-01-20 E.I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
EP0403159A2 (en) 1989-06-14 1990-12-19 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
EP0420237A1 (en) 1989-09-29 1991-04-03 Eisai Co., Ltd. Biphenylmethane derivative, the use of it and pharmacological compositions containing same
EP0459136A1 (en) 1990-04-27 1991-12-04 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
EP0475206A2 (en) 1990-09-10 1992-03-18 Abbott Laboratories Angiotensin II receptor antagonists
WO1992010097A1 (en) 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
WO1992010180A1 (en) 1990-12-14 1992-06-25 Smithkline Beecham Plc Use of angiotensin ii antagonist in the treatment of infarction
EP0504888A1 (en) 1991-03-21 1992-09-23 G.D. Searle & Co. 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
EP0514198A1 (en) 1991-05-16 1992-11-19 Glaxo Group Limited 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group
WO1993020839A2 (en) 1992-04-10 1993-10-28 Brigham And Women's Hospital, Inc. Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality
WO1993020816A1 (en) 1992-04-13 1993-10-28 Zeneca Limited Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
EP0577025A2 (en) 1992-07-01 1994-01-05 Hoechst Aktiengesellschaft Angiotensin-II-receptorantagonist for the treatment and prophylaxis of coronary heart diseases
US5352788A (en) 1990-03-20 1994-10-04 Elf Sanofi N-substituted heterocyclic derivatives
US5399578A (en) 1990-02-19 1995-03-21 Ciba-Geigy Corp Acyl compounds
WO1995023791A1 (en) 1994-03-04 1995-09-08 Roussel Uclaf Novel tetrasubstituted imidazole derivatives, method for preparing same, resulting novel intermediates, use thereof as drugs, and pharmaceutical compositions containing same
WO1995023792A1 (en) 1994-03-04 1995-09-08 Roussel Uclaf Use of imidazole derivatives for treating disorders involving angiotensin receptors at1 and at2, certain such products, preparation thereof, use thereof as drugs, and pharmaceutical compositions containing same
EP0702013A2 (en) 1994-09-15 1996-03-20 MERCK PATENT GmbH Imidazopyridines
WO1996031234A1 (en) 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
WO1997021436A1 (en) 1995-12-12 1997-06-19 Merck & Co., Inc. New use for losartan
US5696116A (en) 1993-07-15 1997-12-09 Hoffmann-La Roche Inc. Pharmaceutical composition which contains a renin angiotensin system inhibitor and an endothelin antagonist
US5696118A (en) 1994-06-01 1997-12-09 Kureha Chemical Industry Co., Ltd. Benzene derivatives and pharmaceutical composition
WO1997049392A1 (en) 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
WO1997049394A2 (en) 1996-06-27 1997-12-31 Novartis Ag Sold oral dosage forms of valsartan
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
US5795904A (en) 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach
WO1999020260A2 (en) 1997-10-17 1999-04-29 Eurogene Limited The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
US6544968B2 (en) * 1999-01-26 2003-04-08 Novartis Ag Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US20070021491A1 (en) * 1999-08-30 2007-01-25 Bernward Scholkens Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Patent Citations (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0253310A2 (en) 1986-07-11 1988-01-20 E.I. Du Pont De Nemours And Company Angiotensin II receptor blocking imidazoles
EP0403159A2 (en) 1989-06-14 1990-12-19 Smithkline Beecham Corporation Imidazolyl-alkenoic acids
EP0420237A1 (en) 1989-09-29 1991-04-03 Eisai Co., Ltd. Biphenylmethane derivative, the use of it and pharmacological compositions containing same
US5399578A (en) 1990-02-19 1995-03-21 Ciba-Geigy Corp Acyl compounds
US5352788A (en) 1990-03-20 1994-10-04 Elf Sanofi N-substituted heterocyclic derivatives
EP0459136A1 (en) 1990-04-27 1991-12-04 Takeda Chemical Industries, Ltd. Benzimidazole derivatives, their production and use
EP0475206A2 (en) 1990-09-10 1992-03-18 Abbott Laboratories Angiotensin II receptor antagonists
WO1992010180A1 (en) 1990-12-14 1992-06-25 Smithkline Beecham Plc Use of angiotensin ii antagonist in the treatment of infarction
WO1992010097A1 (en) 1990-12-14 1992-06-25 Smithkline Beecham Corporation Angiotensin ii receptor blocking compositions
EP0504888A1 (en) 1991-03-21 1992-09-23 G.D. Searle & Co. 5-Arylheteroarylalkyl-1,3,5-trisubstituted-1,2,4-triazole compounds for treatment of circulatory disorders
EP0514198A1 (en) 1991-05-16 1992-11-19 Glaxo Group Limited 1H-Imidazol-1-yl-methyl benzofuran derivatives with the imidazolyl moiety being substituted by a cycloalkyl group
WO1993020839A2 (en) 1992-04-10 1993-10-28 Brigham And Women's Hospital, Inc. Use of renin-angiotensin antagonist for reducing post myocardial infarct mobidity and mortality
WO1993020816A1 (en) 1992-04-13 1993-10-28 Zeneca Limited Angiotensin ii antagonists against disorders associated with impaired neuronal conduction velocity, especially diabetic neuropathy
US5475004A (en) 1992-07-01 1995-12-12 Hoechst Aktiengesellschaft Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
EP0577025A2 (en) 1992-07-01 1994-01-05 Hoechst Aktiengesellschaft Angiotensin-II-receptorantagonist for the treatment and prophylaxis of coronary heart diseases
US5612365A (en) 1992-07-01 1997-03-18 Hoechst Aktiengesellschaft Angiotensin II receptor antagonists for the treatment and prophylaxis of coronary heart disease
EP0634175B1 (en) 1993-07-15 2001-01-10 F. Hoffmann-La Roche Ag Pharmaceutical combination, containing a renin-angiotensin-system inhibitor and an endothelin antagonist
US5696116A (en) 1993-07-15 1997-12-09 Hoffmann-La Roche Inc. Pharmaceutical composition which contains a renin angiotensin system inhibitor and an endothelin antagonist
RU2146522C1 (en) 1993-07-15 2000-03-20 Ф.Хоффманн - Ля Рош АГ Pharmaceutical preparation
WO1995023792A1 (en) 1994-03-04 1995-09-08 Roussel Uclaf Use of imidazole derivatives for treating disorders involving angiotensin receptors at1 and at2, certain such products, preparation thereof, use thereof as drugs, and pharmaceutical compositions containing same
WO1995023791A1 (en) 1994-03-04 1995-09-08 Roussel Uclaf Novel tetrasubstituted imidazole derivatives, method for preparing same, resulting novel intermediates, use thereof as drugs, and pharmaceutical compositions containing same
US5811445A (en) 1994-03-04 1998-09-22 Roussel Uclaf Method of preventing abnormal stimulation of AT1 and AT2 receptors
US5977155A (en) 1994-03-04 1999-11-02 Hoechst Marion Roussel Imidazole-5-carboxamides
US5696118A (en) 1994-06-01 1997-12-09 Kureha Chemical Industry Co., Ltd. Benzene derivatives and pharmaceutical composition
EP0702013A2 (en) 1994-09-15 1996-03-20 MERCK PATENT GmbH Imidazopyridines
US5684015A (en) 1994-09-15 1997-11-04 Merck Patent Gesellschaft Mit Beschrankter Haftung Imidazopyridines as pharmaceutical agents
WO1996031234A1 (en) 1995-04-07 1996-10-10 Novartis Ag Combination compositions containing benazepril or benazeprilat and valsartan
US5795905A (en) 1995-06-06 1998-08-18 Neurocrine Biosciences, Inc. CRF receptor antagonists and methods relating thereto
WO1997021436A1 (en) 1995-12-12 1997-06-19 Merck & Co., Inc. New use for losartan
WO1997049392A1 (en) 1996-06-24 1997-12-31 Merck & Co., Inc. A composition of enalapril and losartan
WO1997049394A2 (en) 1996-06-27 1997-12-31 Novartis Ag Sold oral dosage forms of valsartan
US5795904A (en) 1996-12-06 1998-08-18 Merck & Co., Inc. Enhanced functional recovery of the heart by losartan treatment after an ischemic attach
US6201002B1 (en) 1997-01-10 2001-03-13 Merck & Co., Inc. Method for reducing mortality with an angiotensin II antagonist
WO1999020260A2 (en) 1997-10-17 1999-04-29 Eurogene Limited The use of inhibitors of the renin-angiotensin system for the treatment of hypoxia or impaired metabolic function
US6544968B2 (en) * 1999-01-26 2003-04-08 Novartis Ag Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US6767905B2 (en) * 1999-01-26 2004-07-27 Novartis, Ag Use of angiotensin II receptor antagonists for treating acute myocardial infarction
US20070021491A1 (en) * 1999-08-30 2007-01-25 Bernward Scholkens Use of inhibitors of the renin-angiotensin system in the prevention of cardiovascular events

Non-Patent Citations (26)

* Cited by examiner, † Cited by third party
Title
"Cardiology in Tables and Diagrams", edited by M. Freed and C. Grines, Practika, Moscow, 1996, pp. 110-111, 188-189 (Engtlis Translation from Russian document attached).
Bajzer et al., "Acute Myocardial Infarction", The Cleveland Clinic, published May 30, 2002.
Ceiler, Nelissen-Vrancken, De Mey and Smits, "Effect of Chronic Blockade of Angiotensin II-Receptor Subtypes on Aortic Compliance in Rats with Myocardial Infarction", J Cardiovasc Pharmacol, vol. 31, No. 4, pp. 630-637 (1998).
Di Pasquale et al., "Safety, Tolerability, and Neurohormonal Changes of the Combination Captopril Plus Losartan in the Early Postinfarction Period: A Pilot Study", Cardiovasc Drug Ther, vol. 12, No. 2, pp. 211-216 (1998).
Dickstein et al., Comparison of the effects of losartan and captipril on mortality in patients after acute myocardial infarction: The OPTIMAAL Trial Design 83: 477-481(1999).
Dixon, Ju, Jassal and Peterson, "Effect of Ramipril and Losartan on Collagen Expression in Right and Left Heart after Myocardial Infarction", Mol Cell Biochem, vol. 165, No. 1, pp. 31-45 (1996).
Gold et al., "ACE inhibitors vs. angiotensin II receptor blockers in acute myocardial infarction and heart failure", WMJ, vol. 103, No. 1 (2004).
Hanatani et al., "Inhibition by Angiotensin II Type 1 Receptor Antagonist of Cardiac Phenotypic Modulation after Myocardial Infarction", J Mol Cell Cardiol, vol. 27, pp. 1905-1914 (1995).
Harrison's Principles of Internal Medicine, 13th Edition, vol. 1, (1994) pp. 1077-1085. *
Hayashi et al., "Pharmacological Profile of Valsartan, A Non-Peptide Angiotensin II Type 1 Receptor Antagonist", Arzneim-Forsch/Drug Res, vol. 47, No. 5, pp. 625-629 (1997).
Jalowy et al., AT1 receptor blockade in experimental myocardial ischemia/reperfusion J. Am. Soc. Nephrol 10; pp. S129-S136 (1999).
Lee et al., "Losartan attenuates myocardial ischemia-induced ventricular arrhythmias and reperfusion injury in spontaneously hypertensive rats", American Hypertension, 10, pp. 852-858, no date provided.
Makino et al., "Losartan pretreatment inhibits an early activation of matrix metalloproteinases in acute myocardial infarction" pp. 459-469 (1998).
Makino et al., "Regression of Hypertrophy After Myocardial Infarction is Produced by the Chronic Blockade of Angiotensin Type 1 Receptor in Rats", J Mol Cell Cardiol, vol. 28, No. 3, pp. 507-517 (1996).
Nishikimi et al., "An angiotensin II receptor antagonist attenuates left ventricular dilation after myocardial infarction in the hypertensive rat", Cardiovascular Research, 29, pp. 856-861 (1995).
Pasquale et al., "Safety, tolerability, and neurohormonal changes of the combination captopril plus losartan in the early postinfarction period: A Pilot Study," Therapy, 12, pp. 211-216 (1998).
Pfeffer et al., "Valsartan in acute myocardial infarction trial (Valiant): Rationale and design" Trial Design, J. Am. Heart, 140, 2000, 727-734 (2003).
Pfeffer et al., "Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, of both", Indian heart J.. 55, pp. 669-671 (2003).
Pfeffer et. al., Valsartan, Captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, of both, The New England journal of Medicine, vol. 349; 1893-1906 (2003).
Shen et al., "Combined Effects of Angiotensin Converting Enzyme Inhibition and Angiotensin II Receptor Antagonism in Coscious Pigs with Congestive Heart Failure", Cardiovasc Res, vol. 39, No. 2, pp. 413-422 (1998).
Sumarokov et al. "Clinical cardiology. Handbook for physicians", Moscow, Universum Publishing 1995, pp. 27-28 (English Translation from Russian document attached).
Sun et al., Angiotensin II Receptor Binding Following Myocardial Infarction in the Rat, Cardiovasc Res, vol. 28, No. 11, pp. 1623-1628 (1994).
Taylor et al., "Divergent Effects of Angiotensin-Converting Enzyme Inhibition and Angiotensin II-Receptor Antagonism on Myocardial Cellular Proliferation and Collagen Deposition After Myocardial Infarction in Rats", J Cardiovasc Pharmacol, vol. 31, No. 5, pp. 654-660 (1998).
The Merck Manual of Diagnosis and Therapy, Seventeenth Edition, pp. 1668-1681 (1999).
Valiant Study Results , About Valiant and other clinical research supporting diovan.(2005).
Youn et al., "Ventricular remodeling and transforming growth factor-beta 1 mRNA expression after nontransmural myocardial infarction in rats: effects of angiotensin converting enzyme inhibition and angiotensin II type 1 receptor blockade", Basic Res. Card, date not provided.

Also Published As

Publication number Publication date
US20040224999A1 (en) 2004-11-11
US20020042436A1 (en) 2002-04-11
US20030166699A1 (en) 2003-09-04
US6767905B2 (en) 2004-07-27
ZA200106022B (en) 2002-08-21
CN101011390A (en) 2007-08-08
US6544968B2 (en) 2003-04-08

Similar Documents

Publication Publication Date Title
RU2345790C2 (en) Application of angiotensin ii receptor antagonists for treatment of acute myocardial infarction
EP1467728B1 (en) Pharmaceutical compositions comprising valsartan and nep inhibitors
RU2298418C2 (en) Combination of at least two compounds chosen from groups at1-receptor antagonists or inhibitors of ace (angiotensin-converting enzyme) or inhibitors of hmg-coa-reductase (beta-hydroxy-beta-methylglutaryl-coenzyme-a-reductase)
AU2001225816B2 (en) Therapeutic combination of amlodipine and benazepril
JP5968927B2 (en) Drug composition used for the treatment of hypertension and metabolic syndrome and its application
US7560446B2 (en) Use of angiotensin II receptor antagonists for treating acute myocardial infarction
KR101414814B1 (en) Complex formulation comprising lercanidipine hydrochloride and valsartan and method for the preparation thereof
US20070123498A1 (en) Combination of organic compounds
AU2005209657A1 (en) Combination of at least two compounds selected from an AT1-Receptor antagonist or an ACE inhibitor or a HMG-CO-A reductase inhibitor group

Legal Events

Date Code Title Description
REMI Maintenance fee reminder mailed
LAPS Lapse for failure to pay maintenance fees
STCH Information on status: patent discontinuation

Free format text: PATENT EXPIRED DUE TO NONPAYMENT OF MAINTENANCE FEES UNDER 37 CFR 1.362

FP Lapsed due to failure to pay maintenance fee

Effective date: 20130714